<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03828682</url>
  </required_header>
  <id_info>
    <org_study_id>2018-7742</org_study_id>
    <nct_id>NCT03828682</nct_id>
  </id_info>
  <brief_title>Veloxis de Novo Kidney Transplant ECSWD</brief_title>
  <official_title>A 12-Month, Open Label Study of Extended Release Tacrolimus (Envarsus XR®, LCPT) With Mycophenolate, Rabbit Antithymocyte Globulin (rATG) and Early Steroid Withdrawal in de Novo Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Simon Tremblay, PharmD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veloxis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and efficacy of LCPT in combination with rATG,
      mycophenolate and early corticosteroid withdrawal (CSWD) in de novo kidney transplant
      recipients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A prospective cohort of de novo kidney transplant recipients will be assigned to treatment group and compared to historical controls</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with the combination oral outcome of Biopsy-proven acute rejection, patient death and graft loss</measure>
    <time_frame>12 months</time_frame>
    <description>Biopsy-proven acute rejection, patient death and graft loss</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Prospective Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>De novo kidney transplant recipients receiving:
rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Once-daily tacrolimus XR 0.8mg/kg/day started when or when serum creatinine is &lt;4mg/dL or by 48 hours of transplant to target 24-hr trough levels of 8-12ng/mL up to day 30 followed by 24-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Historical control arm consisting of the following
De novo kidney transplant recipients receiving:
rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Twice-daily tacrolimus 0.1mg/kg/day started when or when serum creatinine is &lt;4mg/dL or by 48 hours of transplant to target 12-hr trough levels of 8-12ng/mL up to day 30 followed by 12-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Extended Release Oral Tablet [Envarsus]</intervention_name>
    <description>Tacrolimus Extended Release Oral Tablet [Envarsus]</description>
    <arm_group_label>Prospective Arm</arm_group_label>
    <other_name>Envarsus XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Mycophenolate mofetil capsules or tablets</description>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_label>Prospective Arm</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic Acid Oral Product</intervention_name>
    <description>mycophenolic acid tablets</description>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_label>Prospective Arm</arm_group_label>
    <other_name>Myfortic</other_name>
    <other_name>MPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Twice daily tacrolimus</description>
    <arm_group_label>Comparator arm</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone taper</description>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_label>Prospective Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone taper</description>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_label>Prospective Arm</arm_group_label>
    <other_name>Deltasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]</intervention_name>
    <description>Rabbit Anti-Human T-Lymphocyte Globulin</description>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_label>Prospective Arm</arm_group_label>
    <other_name>Thymoglobulin</other_name>
    <other_name>rATG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients ≥ 18 years of age.

          2. Patient who is receiving a renal transplant from a living or heart-beating deceased
             donor.

          3. Female patients of child bearing potential must have a negative urine or serum
             pregnancy test within the past 48 hours prior to study inclusion.

          4. The patient has given written informed consent to participate in the study

        Exclusion Criteria:

          1. Patient has previously received an organ transplant other than a kidney.

          2. Patient is receiving an HLA identical living donor transplant.

          3. Patient who is a recipient of a multiple organ transplant.

          4. Patient has a most recent cytotoxic PRA of &gt;25% or calculated PRA &gt;50% where multiple
             moderate level HLA antibodies exist and in the opinion of the PI represents
             substantial HLA sensitization.

          5. Patient with a positive T or B cell crossmatch that is primarily due to HLA
             antibodies.

          6. Patient with a donor specific antibody (DSA) as deemed by the PI to be associated with
             significant risk of rejection.

          7. Patient has received an ABO incompatible donor kidney.

          8. The deceased donor and/or deceased donor kidney meet any of the following extended
             criteria for organ donation (ECD):

               1. Donor age ≥ 60 years OR

               2. Donor age 50-59 years and 1 of the following:

             i. Cerebrovascular accident (CVA) + hypertension + SCr &gt; 1.5 mg/dL OR ii. CVA +
             hypertension OR iii. CVA + SCr &gt; 1.5 mg/dL OR iv. Hypertension + SCr &gt; 1.5 mg/dL OR c.
             CIT ≥ 24 hours, donor age &gt; 10 years OR d. Donation after cardiac death (DCD)

          9. Recipients will be receiving a dual or en bloc kidney transplant.

         10. Donor anticipated cold ischemia is &gt;30hours.

         11. Recipient that is seropositive for hepatitis C virus (HCV) with detectable Hepatitis C
             viral load are excluded. HCV seropositive patients with a negative HCV viral load
             testing may be included.

         12. Recipients with a positive hepatitis B viral load or positive hepatitis B surface
             antigen testing within 1 year of consent.

         13. Hepatitis B surface antibody negative recipients receiving a kidney from a donor
             seropositive for hepatitis B core antibody or hepatitis B nucleic acid.

         14. Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV).

         15. Recipient who is seronegative for Epstein Barr Virus (EBV)

         16. Patient has uncontrolled concomitant infection or any other unstable medical condition
             that could interfere with the study objectives.

         17. Patients with thrombocytopenia (PLT &lt;75,000/mm3), and/or leukopenia (WBC &lt; 2,000/mm3),
             or anemia (hemoglobin &lt; 6 g/dL) prior to study inclusion.

         18. Patient is taking or has been taking an investigational drug in the 30 days prior to
             transplant.

         19. Patient who has undergone desensitization therapy within 6 months prior to transplant.

         20. Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil/mycophenolic
             acid, rabbit anti-thymocyte globulin, or glucocorticoids.

         21. Patient is receiving chronic steroid therapy at the time of transplant.

         22. Patients with a history of cancer (other than non-melanoma skin cell cancers cured by
             local resection) within the last 5 years, unless they have an expected disease free
             survival of &gt;95%.

         23. Patient is pregnant, where pregnancy is defined as the state of a female after
             conception and until the termination of gestation, confirmed by positive human
             Chorionic Gonadotropin (hCG) laboratory test.

         24. Women of childbearing potential must use reliable contraception simultaneously, unless
             they are status post bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy.

         25. Patient has any form of substance abuse, psychiatric disorder or a condition that, in
             the opinion of the investigator, may invalidate communication with the investigator.

         26. Inability to cooperate or communicate with the investigator.

         27. Renal allograft has been reperfused for more than 48 hours at the time of enrollment

         28. Patient unable to receive intact LCPT formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Tremblay, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon Tremblay, PharmD, PhD</last_name>
    <phone>513-558-9967</phone>
    <email>tremblsn@ucmail.uc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Tremblay, PharmD, PhD</last_name>
      <phone>513-558-9967</phone>
      <email>simon.tremblay@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Adele Rike-Shields, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ervin S Woodle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Tremblay, PharmD, PhD</last_name>
      <phone>513-558-9967</phone>
      <email>simon.tremblay@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Rita R Alloway, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ervin S Woodle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amit Govil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Simon Tremblay, PharmD, PhD</investigator_full_name>
    <investigator_title>Research Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>tacrolimus</keyword>
  <keyword>extended release</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>steroid withdrawal</keyword>
  <keyword>once daily</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

